6505--Dimethyl Fumarate Capsules

The Department of Veterans Affairs National Acquisition Center is soliciting offers for Dimethyl Fumarate Capsules through solicitation number 36E79726R0003. The procurement seeks to establish a pharmaceutical supply contract for two dosage strengths: 120MG capsules (14 per bottle) and 240MG capsules (60 per bottle). Offerors must meet FDA approval requirements, comply with current Good Manufacturing Practices (cGMP), provide a unique 11-digit National Drug Code (NDC) number, and include a 0.5% Cost Recovery Fee in their pricing submissions. The government will evaluate offers using a lowest price technically acceptable (LPTA) criteria, with technical acceptability determined by meeting FDA, packaging, and other specified requirements. The solicitation due date has been extended to December 9, 2025, at 2:30 PM CST, allowing interested contractors additional time to prepare and submit their proposals.

This procurement carries no set-aside designation and is available to all qualified contractors, including small businesses with a size standard of 1,300 employees. The contract will cover a base year plus four one-year option periods, with estimated annual usage of 3,200 bottles of the 120MG strength and 21,737 bottles of the 240MG strength across the VA, Department of Defense, Indian Health Service, and Bureau of Prisons. Distribution of awarded products will occur through Prime Vendor contractors, including McKesson Corporation. Offerors must submit pricing for the base year and all four option years, and those who are not small businesses must submit a subcontracting plan. While specific award values are not disclosed in the solicitation documents, the significant annual quantities indicate substantial procurement volume for the successful contractor.